Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder

NCT02659085 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2019-12-19

No results posted yet for this study

Summary

Developing more effective and faster acting antidepressant is of outmost clinical importance. Available antidepressant therapies have a delayed therapeutic effect. It typically takes several weeks before symptom relief is evident. Furthermore, antidepressants are relatively ineffective - as many as 30% of patients do not respond to any medication at all. In this study the investigators evaluate the NMDA-receptor antagonist ketamine as a potentially new antidepressant treatment for severely depressed patients and compare its effectiveness with that of electroconvulsive therapy (ECT).

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Ketamine IV Infusion

Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.

PROCEDURE

ECT

ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.

Sponsors & Collaborators

  • Pouya Movahed Rad

    lead OTHER

Principal Investigators

  • Pouya Movahed Rad, MD, PhD · Dept of Clinical Sciences Lund, Faculty of Medicine Lund University, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02659085 on ClinicalTrials.gov